摘要
综述多廿醇在治疗心血管疾病方面的临床及基础研究,探讨其可能涉及的机制。
出处
《华西药学杂志》
CAS
CSCD
北大核心
2008年第4期456-458,共3页
West China Journal of Pharmaceutical Sciences
基金
国家自然科学基金课题(批准号:30360091)
参考文献19
-
1[1]Arruzazabala ML,Noa M,Menendez R,et al.Protective effect of policosanol on atheresclerotic lesions in rabbits with exogenous hypercholesterolemia[J].Braz J Med Biol Bes,2000,33(7):835-840.
-
2[2]Gouni-berthold I,Berthold HK.Policosanol:clinical phartautology and therapeutic signifieance of a new lipid,lowering agent[J].Am Heart,2002,143(2):356 -365.
-
3[3]Mccarty MF.An ezetimibe-pnheesanol combination has the potential to be an OTC agent that could dramatically lower LDL cholesterol without side effects[J].Med Hypotheses,2005,64 (3):636 -645.
-
4[4]Todeschi-reiner E,Reiner Z,Bernie Z,et al,A randomized,double-blind,placebo-controlled study of theantilipemic efficacy and tolerability of food supplement palicosanol in patients with moderate hypereholesterolemia[J].Lijec Vjesn,2005,127 (11-12):273 -279.
-
5[5]Castano,Gladys,MAS,et al.Comparison of the Efficacy and Tolerability of Polieesanol with Atorvastatin in Elderly Patients with Type Ⅱ Hypercholesterolaemia[J].Drugs & Aging,2003,20 (2):153-163.
-
6崔艳丽,赵秀丽,武峰,郭韶洁,李嘉静,周辉,杨凌,尚军.胆固醇酯转运蛋白基因TaqⅠ多态性与多廿烷醇降脂疗效的关系[J].中国新药杂志,2007,16(3):240-243. 被引量：4
-
7[7]Mirkin A,Mas R,Martinto M,et al.Efficacy and tolerability of pelicosanol in hypercholesterolemic postmenopausal women[J].Int J Clin Pharmacol Res,2001,21 (1):31 -41.
-
8[8]Mas R,Castano G,Fernandez L,et al.Effects of Policosanol on Lipid Profile and Cardiac Events in Older Hypercholesterolaemic Patients with Coronary Disease[J].Clin Drug Inv,2001,21 (7):485-497.
-
9[9]Arruzazabela ML,Molina V,Mas R,et al.Antiplatelet effects of poliecsanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients[J].Clin and Exp Pharmac Physiol,2002,29 (7):891 -897.
-
10[10]Menendez R,Mas R,Amor AM,et al.Effects of palicosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modillcation in vitro[J].Br J Clin Pharmacol,2000,50(3):255 -262.
共引文献3
-
1庞伟毅,何凤英,韦小敏.多廿醇对高脂血症大鼠血清胆固醇水平的影响[J].中国药理学与毒理学杂志,2009,23(6):443-449. 被引量：2
-
2应茵,陆绪亮,董威夷,宋洪涛.10mg多廿烷醇与等剂量阿托伐他汀在血脂异常患者中调脂疗效比较的荟萃分析[J].药学实践杂志,2017,35(3):282-288. 被引量：2
-
3吕晨铃,张震中,金笑平.CETP基因Taq IB位点多态性对血脂水平及他汀疗效的影响[J].医学研究杂志,2018,47(9):90-96.
同被引文献6
-
1窦晓兵,范春雷,胡林峰,钱颖,沃兴德.胶体金-荧光素双标配体法研究细胞低密度脂蛋白受体的功能[J].中国药学杂志,2007,42(10):729-732. 被引量：2
-
2Gouni - Berthold I, Berthold HK. Policosanol clinical pharmacology and therapeutic significance of a new lipid - lowering agent [ J ]. Am Heart J,2004,143 ( 2 ) : 356 - 365.
-
3Chen JT, Wesley R, Shamburek RD, et al. Meta - analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol [ J ]. Pharmacotherapy ,2005,25 (2) : 171 - 183.
-
4Menendez R, Fernandez SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts [ J ]. Biol Res, 1994,27 (3 -4) :199 -203.
-
5庞伟毅,何凤英,韦小敏.多廿醇降胆固醇及抗氧化作用的实验研究[J].华西药学杂志,2009,24(4):331-333. 被引量：3
-
6李宝华,郑广娟,张文高,张静,张丹.软脉降脂胶囊对实验性高脂血症大鼠血脂及MDA、SOD、NO的影响[J].中西医结合心脑血管病杂志,2004,2(4):220-222. 被引量：18
